# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- Reuters
Published data show that topical Sildenafil Cream, 3.6% was safe and well tolerated by women and their partners across 1,357 se...
Maxim Group analyst Caroline Palomeque downgrades Dare Bioscience (NASDAQ:DARE) from Buy to Hold.
Published data show that responses from 1-month and 24-hour recall patient reported outcome (PRO) instruments were similar and ...
Dare Bioscience (NASDAQ:DARE) reported quarterly earnings of $1.52 per share. The company reported $22.438 million in sales th...
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in innovation for the health and wellbeing of women, announced that it was notif...
Shares Expected to Begin Trading on Split-Adjusted Basis on July 1, 2024SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) -- Daré Biosc...